Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness ...

Data shows adding durvalumab (Imfinzi) to the standard chemotherapy combination known as FLOT before and after surgery kept ...

Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall ...

A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to ...

Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM). This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This ...